This page is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
I added a new section to the Glioblastoma page under "Research" and it was removed. I am trying to understand why it was removed so I can edit my submission and repost for approval. Can you tell me why it may have been removed?
Cancer immunotherapy Imvax is a clinical-stage biotechnology company with a platform technology focused on delivering personalized, whole tumor-derived immunotherapy. The most advanced program in their pipeline, IGV-001, is currently in development to treat glioblastoma1. The company has already completed a Phase 1a in recurrent glioblastoma and a Phase 1b in newly diagnosed glioblastoma (ndGBM)2. Imvax initiated a Phase 2b clinical trial of IGV-001 in ndGBM patients in March 2023. The trial is expected to enroll up to 93 participants in a 2:1 randomization across approximately 25 sites in the United States3.
1 Andrews DW, Judy KD, Scott CB, Garcia S, Harshyne LA, Kenyon L, Talekar K, Flanders A, Atsina KB, Kim L, Martinez N, Shi W, Werner-Wasik M, Liu H, Prosniak M, Curtis M, Kean R, Ye DY, Bongiorno E, Sauma S, Exley MA, Pigott K, Hooper DC. Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res. 2021 Apr 1;27(7):1912-1922. doi: 10.1158/1078-0432.CCR-20-3805. Epub 2021 Jan 26. PMID: 33500356. 2 David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosniak, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, D. Craig Hooper; Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res 1 April 2021; 27 (7): 1912–1922. https://doi.org/10.1158/1078-0432.CCR-20-3805 3 A phase 2B clinical study with a combination immunotherapy in newly diagnosed patients with glioblastoma - full text view. Full Text View - ClinicalTrials.gov. (n.d.) -- Thomastenbridge ( talk) 14:43, 24 May 2023 (UTC)
News and updates for administrators from the past month (May 2023).
|
|
Guild of Copy Editors June 2023 Newsletter
Hello and welcome to the June 2023 newsletter, a quarterly digest of Guild activities since March. Don't forget you can unsubscribe at any time; see below. Election news: Fancy helping out at the Guild? Nominations for our half-yearly Election of Coordinators are open until 23:59 on 15 June (UTC)*. Starting immediately after, the voting phase will run until 23:59 on 30 June. All Wikipedians in good standing are eligible and self-nominations are welcomed; it's your Guild and it doesn't organize itself! Blitz: Of the 17 editors who signed up for our April Copy Editing Blitz, nine editors completed at least one copy-edit. Between them, they copy-edited 24 articles totaling 53,393 words. Barnstars awarded are here. Drive: 51 editors signed up for the month-long May Backlog Elimination Drive, and 31 copy-edited at least one article. 180 articles were copy-edited. Barnstars awarded are posted here. Blitz: Sign up here for our week-long June Copy Editing Blitz, which runs from 11 to 17 June. Barnstars awarded will be posted here. Progress report: As of 03:09 on 6 June 2023, GOCE copyeditors have processed 91 requests since 1 January and the backlog stands at 1,887 articles. Thank you all again for your participation; we wouldn't be able to achieve what we have without you! Cheers from your GOCE coordinators Baffle gab1978, Dhtwiki, Miniapolis and Zippybongo. *All times and dates in this newsletter are in UTC, and may significantly vary from your local time. To discontinue receiving GOCE newsletters, please remove your name from
our mailing list.
|
Sent by Baffle gab1978 using MediaWiki message delivery ( talk) 03:38, 6 June 2023 (UTC)
Hi IXtal, Since Wikipedia assigned you as my mentor, I assumed I could ask you a question. I was copy-editing the page PDF-XChange Viewer to remove promotional content. In that way, I removed a promotional sentence, which was sourced. I therefore removed the source is well. But is this considered good practice? Or should I have discussed it on the talk page before? Ahossai ( talk) -- Ahossai ( talk) 09:51, 15 June 2023 (UTC)
I’m new to editing. How do I upload the changes now? -- Knocklofty ( talk) 00:20, 22 June 2023 (UTC)
This page is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
I added a new section to the Glioblastoma page under "Research" and it was removed. I am trying to understand why it was removed so I can edit my submission and repost for approval. Can you tell me why it may have been removed?
Cancer immunotherapy Imvax is a clinical-stage biotechnology company with a platform technology focused on delivering personalized, whole tumor-derived immunotherapy. The most advanced program in their pipeline, IGV-001, is currently in development to treat glioblastoma1. The company has already completed a Phase 1a in recurrent glioblastoma and a Phase 1b in newly diagnosed glioblastoma (ndGBM)2. Imvax initiated a Phase 2b clinical trial of IGV-001 in ndGBM patients in March 2023. The trial is expected to enroll up to 93 participants in a 2:1 randomization across approximately 25 sites in the United States3.
1 Andrews DW, Judy KD, Scott CB, Garcia S, Harshyne LA, Kenyon L, Talekar K, Flanders A, Atsina KB, Kim L, Martinez N, Shi W, Werner-Wasik M, Liu H, Prosniak M, Curtis M, Kean R, Ye DY, Bongiorno E, Sauma S, Exley MA, Pigott K, Hooper DC. Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res. 2021 Apr 1;27(7):1912-1922. doi: 10.1158/1078-0432.CCR-20-3805. Epub 2021 Jan 26. PMID: 33500356. 2 David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosniak, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, D. Craig Hooper; Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res 1 April 2021; 27 (7): 1912–1922. https://doi.org/10.1158/1078-0432.CCR-20-3805 3 A phase 2B clinical study with a combination immunotherapy in newly diagnosed patients with glioblastoma - full text view. Full Text View - ClinicalTrials.gov. (n.d.) -- Thomastenbridge ( talk) 14:43, 24 May 2023 (UTC)
News and updates for administrators from the past month (May 2023).
|
|
Guild of Copy Editors June 2023 Newsletter
Hello and welcome to the June 2023 newsletter, a quarterly digest of Guild activities since March. Don't forget you can unsubscribe at any time; see below. Election news: Fancy helping out at the Guild? Nominations for our half-yearly Election of Coordinators are open until 23:59 on 15 June (UTC)*. Starting immediately after, the voting phase will run until 23:59 on 30 June. All Wikipedians in good standing are eligible and self-nominations are welcomed; it's your Guild and it doesn't organize itself! Blitz: Of the 17 editors who signed up for our April Copy Editing Blitz, nine editors completed at least one copy-edit. Between them, they copy-edited 24 articles totaling 53,393 words. Barnstars awarded are here. Drive: 51 editors signed up for the month-long May Backlog Elimination Drive, and 31 copy-edited at least one article. 180 articles were copy-edited. Barnstars awarded are posted here. Blitz: Sign up here for our week-long June Copy Editing Blitz, which runs from 11 to 17 June. Barnstars awarded will be posted here. Progress report: As of 03:09 on 6 June 2023, GOCE copyeditors have processed 91 requests since 1 January and the backlog stands at 1,887 articles. Thank you all again for your participation; we wouldn't be able to achieve what we have without you! Cheers from your GOCE coordinators Baffle gab1978, Dhtwiki, Miniapolis and Zippybongo. *All times and dates in this newsletter are in UTC, and may significantly vary from your local time. To discontinue receiving GOCE newsletters, please remove your name from
our mailing list.
|
Sent by Baffle gab1978 using MediaWiki message delivery ( talk) 03:38, 6 June 2023 (UTC)
Hi IXtal, Since Wikipedia assigned you as my mentor, I assumed I could ask you a question. I was copy-editing the page PDF-XChange Viewer to remove promotional content. In that way, I removed a promotional sentence, which was sourced. I therefore removed the source is well. But is this considered good practice? Or should I have discussed it on the talk page before? Ahossai ( talk) -- Ahossai ( talk) 09:51, 15 June 2023 (UTC)
I’m new to editing. How do I upload the changes now? -- Knocklofty ( talk) 00:20, 22 June 2023 (UTC)